Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Read original at benzingaStocks · News reference
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 12:40 PM
- Checked
- Jul 21, 2026, 12:40 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.
Read original at benzingaBarclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.
Read original at benzingaMizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
Read original at benzinga